Opinion|Videos|February 14, 2025

MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.

Episodes in this series

  1. Provide an overview of the current landscape of induction therapies for MCL. What role do BTK inhibitors have in this landscape?
    1. Aggressive induction therapy

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo